Watson Launches Generic AMRIX

Watson Pharmaceuticals, Inc. WPI today confirmed that its subsidiary, Watson Pharma, Inc., has launched an authorized generic version of AMRIX 15 mg and 30 mg, as part of an agreement with Anesta AG, a subsidiary of Cephalon, Inc. AMRIX is approved for use along with rest and physical therapy to help control muscle spasm associated with acute, painful musculoskeletal conditions.